NCT05749666 (TOFGCTAK) is a Phase 3 clinical trial of Tofacitinib 5 MG in Takayasu Arteritis, sponsored by Chinese SLE Treatment And Research Group.

Who is sponsoring NCT05749666?

NCT05749666 is sponsored by Chinese SLE Treatment And Research Group.

What drugs are being tested in NCT05749666?

Interventions in NCT05749666: Tofacitinib 5 MG, Prednisolone, Placebo of tofacitinib 5mg, Placebo of prednisolone.

What condition does NCT05749666 study?

NCT05749666 studies Takayasu Arteritis.

Is NCT05749666 still recruiting?

NCT05749666 is currently status unknown. Last updated 1 March 2023.

Last reviewed 2023-03-01 · How we verify

NCT05749666: TOFGCTAK

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparison of Tofacitinib and Prednisolone in the Treatment of Active Takayasu's Arteritis

Status unknown Phase 3 Last updated 1 March 2023

What this trial tests

Phase 3 trial testing Tofacitinib 5 MG in Takayasu Arteritis in 50 participants. Status unknown.

Timeline

20 January 2023

Primary endpoint
20 July 2025

20 July 2025

Quick facts

Lead sponsor	Chinese SLE Treatment And Research Group
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	50
Start date	20 January 2023
Primary completion	20 July 2025
Estimated completion	20 July 2025
Sites	1 location across China

Drugs / interventions tested

Tofacitinib 5 MG (tofacitinib-5-mg) — full drug profile →
Prednisolone — full drug profile →
Placebo of tofacitinib 5mg
Placebo of prednisolone

Conditions studied

Takayasu Arteritis — all drugs for Takayasu Arteritis →

Sponsor

Chinese SLE Treatment And Research Group

Who can join

Adults 18 to 65, any sex, with Takayasu Arteritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, double-blinded, single center, randomized clinical trial. It compares the clinical efficacy and safety of thees 2 drugs in the treatment of active Takayasu's arteritis patients.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

A Glimpse into Humoral Response and Related Therapeutic Approaches of Takayasu's Arteritis.
Guo S, Tian Y, Li J, Zeng X. · · 2024 · cited 2× · PMID 38928233 · DOI 10.3390/ijms25126528

Verify or expand the search:

Other trials of Tofacitinib 5 MG

Trials testing the same drug.

NCT06201715 — Efficacy and Safety of Tofacitinib in Patients With Prurigo Nodularis · NA · unknown
NCT06202560 — Effectiveness and Safety of Tofacitinib in Patients With Recalcitrant Frontal Fibrosing Alopecia : A Pilot Study · NA · completed
NCT05151848 — Comparison of Adalimumab and Tofacitinib in the Treatment of Active Takayasu Arteritis · Phase 4 · unknown
NCT04799262 — Tofacitinib as a GC Sparing Agent for Polymyalgia Rheumatica · Phase 2 · completed
NCT04431895 — Safety And Efficacy Of Tofacitinib In Patients With Refractory Myasthenia Gravis: A Pilot Study · EARLY_PHASE1 · completed

Other recruiting trials for Takayasu Arteritis

Currently open trials in the same condition.

NCT07087912 — Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases · Phase 4 · recruiting
NCT07351422 — Investigating Management, Perspectives and Attitudes Towards Care in Takayasu Arteritis · recruiting
NCT07276087 — Physical and Psychosocial Parameters in Takayasu Arteritis and Behçet's Disease: A Comparative Study With Healthy Contro · recruiting
NCT07491913 — Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission · NA · recruiting
NCT06887062 — Dapagliflozin and Endothelin Receptor Antagonism in Large Vessel Vasculitis (DERAIL-LVV) · Phase 2 · recruiting

Other Chinese SLE Treatment And Research Group trials

Trials by the same sponsor.

NCT07381465 — Efficacy and Safety of IL-1 Inhibitors in Mild to Moderate Systemic Lupus Erythematosus · Phase 4 · not yet recruiting
NCT07451665 — Efficacy and Safety of Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's Arteritis · Phase 4 · not yet recruiting
NCT07013838 — The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis · Phase 4 · not yet recruiting
NCT06881290 — Vunakizumab for the Treatment of Mild to Moderate Systemic Lupus Erythematosus · Phase 1 · recruiting
NCT06887517 — Chinese Rheumatism Biobank(CRB) · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05749666 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chinese SLE Treatment And Research Group
Last refreshed: 1 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05749666.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing